The North America Clinical Nutrition Market would witness market growth of 6.2% CAGR during the forecast period (2020-2026).
Nutrition and diet are an important part of many health problems. A person is helped to preserve his health and wellbeing with a healthy diet and healthy intakes. Clinical nutrition is a form of nutrition for patients receiving medical care. Clinical nutrition is structured to preserve energy balance and provide essential nutrients such as calories, vitamins, and minerals. It also includes studies of nutrients important for the human body and the way the body is affected by nutrients.
Treatments for cancer can impair taste, smell, appetite, and ability to consume adequate food or absorb food nutrients. This can lead to malnutrition caused by a lack of important nutrients. The risk of malnutrition can rise with alcohol abuse and obesity. Malnutrition may contribute to fatigue, tiredness, and inability to fight illness or to end treatment of cancer. If cancer grows or spreads, malnutrition may become worse. This stresses the critical importance of clinical nutrition especially for treatment, infection control, and strength.
Neurological problems are also concerned with swallowing and starvation. In fact, the possibility of micronutrient loss and dehydration is enhanced for patients with neurological disorders. In comparison, the pathogenesis of neurological disorders may require dietary factors. The multiple causes of malnutrition are known for oropharyngeal dysphagia, impaired consciously, perception deficits, cognitive dysfunction, and increased need in neurological patients.
Based on Route of Administration, the market is segmented into Oral, Enteral and Parenteral. Based on Application, the market is segmented into Cancer, Neurological Diseases, Gastrointestinal Disorders, Metabolic Disorders and Other Applications. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, B. Braun Melsungen AG, Baxter International, Inc., Pfizer, Inc., Nestle S.A., Lonza Group AG, BASF SE, Ajinomoto Co., Inc., Perrigo Company PLC, and Hero Nutritionals, Inc.
Scope of the Study
By Route of Administration
• Enteral and
• Neurological Diseases
• Gastrointestinal Disorders
• Metabolic Disorders and
• Other Applications
• Rest of North America
• Abbott Laboratories
• B. Braun Melsungen AG
• Baxter International, Inc.
• Pfizer, Inc.
• Nestle S.A.
• Lonza Group AG
• BASF SE
• Ajinomoto Co., Inc.
• Perrigo Company PLC
• Hero Nutritionals, Inc.
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Our reports have been used by over 10K customers, including:
279 pages •
By Global Industry Analysts
• Apr 2021
- Global Single Lead ECG Equipment Market to Reach $508.4 Million by 2027
- Amid the COVID-19 crisis, the global market for Single Lead ECG Equipment estimated at US$372.5 Million in the year 2020, is projected to reach a revised size of US$508.4 Million by 2027, growing at a CAGR of 4.5% over the analysis...
Autism (Central Nervous System) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Autism - Drugs in Development, 2021, provides an overview of the Autism (Central Nervous System) pipeline landscape. Autism, also known as complex developmental...
Restless Legs Syndrome (Central Nervous System) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Drugs in Development, 2021, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape. Restless...
Hepatic Encephalopathy (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Drugs in Development, 2021, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape. Hepatic...
The market studied is expected to witness a rapid growth rate in the future, owing to factors, such as the rising prevalence of multiple sclerosis (MS) and the growing focus of companies on pipeline products for MS. - Big pharmaceutical companies have been investing heavily in the drug development process and are planning to target...
The North America yeast extract market is expected to reach US$ 561.2 million in 2027 from US$ 389.6 million in 2019. The market is estimated to grow at a CAGR of 4.7% during 2020–2027. The growth the North America yeast extract market is attributed to the key driving factors such as the rising demand for natural ingredients in the...
The global pharmaceutical contract development and manufacturing market is projected to reach USD 146.1 billion by 2025 from USD 100.7 billion in 2020, at a CAGR of 7.7% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.